Proteome Sciences PLC
19 April 2000
Proteome Sciences plc ('the Company' or 'Proteome')
Results of Open Offer
On 28 March 2000, Proteome announced the terms of a Placing of 3,777,775 new
Ordinary Shares with certain existing shareholders and the terms of an Open
Offer of up to 10,199,636 new Ordinary Shares to qualifying shareholders.
Proteome announces that in addition to the 3,777,775 new ordinary shares
placed with certain existing shareholders, valid applications have been
received from Qualifying Shareholders for 6,157,268 New Ordinary Shares,
representing 60.3 per cent. of the New Ordinary Shares which were available
for take up under the Open Offer.
Applications received in respect of excess shares will be allocated in full.
The Placing and the Open Offer remain conditional upon admission of the new
Ordinary Shares to trading on AIM and the passing of resolution 1 to be
proposed at the forthcoming Extraordinary General Meeting.
The new Ordinary Shares to be allotted pursuant to the Placing and the Open
Offer are expected to commence trading on AIM at 8.30 a.m. on 25 April 2000.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.